Wolfe Research Begins Coverage on Novo Nordisk A/S (NYSE:NVO)

Key Points

• Wolfe Research initiated coverage of Novo Nordisk with a "peer perform" rating.
• The analyst landscape is mixed—four Buys, nineteen Holds and one Sell—giving a consensus "Hold" and a $65.56 target, with several recent downgrades (e.g., Weiss, Bernstein) weighing on sentiment.
• Fundamentals and news are conflicted: Novo reported an earnings beat with strong margins and revenue, but the stock is trading near recent lows (~$37.37) as pricing pressure (Wegovy cuts) and competitive/launch uncertainty offset positive pipeline updates (UBT251 Phase II, Wegovy HD FDA clearance).

Equities research analysts at Wolfe Research began coverage on shares of Novo Nordisk A/S (NYSE:NVO - Get Free Report) in a research report issued on Thursday. The brokerage set a "peer perform" rating on the stock.

Several other analysts have also issued reports on NVO. Weiss Ratings lowered shares of Novo Nordisk A/S from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Wednesday, March 18th. BMO Capital Markets reiterated a "market perform" rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. Argus reissued a "hold" rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Kepler Capital Markets lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Tuesday, February 24th. Finally, TD Cowen cut Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $42.00 price target for the company. in a report on Tuesday, March 10th. Four research analysts have rated the stock with a Buy rating, nineteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $65.56.

Novo Nordisk A/S Stock Performance

NVO traded up $1.04 during midday trading on Thursday, reaching $37.37. The company's stock had a trading volume of 3,512,952 shares, compared to its average volume of 24,269,750. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The company has a fifty day simple moving average of $46.86 and a 200 day simple moving average of $50.71. The stock has a market cap of $166.86 billion, a P/E ratio of 10.77 and a beta of 0.73. Novo Nordisk A/S has a twelve month low of $35.85 and a twelve month high of $81.44.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The company had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Rockefeller Capital Management L.P. raised its position in Novo Nordisk A/S by 77.2% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,340,858 shares of the company's stock worth $68,223,000 after purchasing an additional 584,275 shares during the last quarter. Larry Mathis Financial Planning LLC bought a new position in Novo Nordisk A/S in the 4th quarter valued at $535,000. PeakShares LLC acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at $491,000. Union Savings Bank acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at $312,000. Finally, Mengis Capital Management Inc. raised its position in shares of Novo Nordisk A/S by 303.2% during the fourth quarter. Mengis Capital Management Inc. now owns 66,694 shares of the company's stock worth $3,393,000 after acquiring an additional 50,154 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Phase II data for triple‑agonist UBT251 showed strong efficacy (mean HbA1c reductions up to ~2.16% and weight loss up to ~9.8% at 24 weeks), supporting broader development plans and bolstering Novo’s longer‑term diabetes/obesity pipeline. WSJ: Novo Nordisk Says Experimental Diabetes and Obesity Drug Shows Positive Results
• Positive Sentiment: FDA clearance of a higher Wegovy dose (Wegovy HD) expands the product’s label and could raise addressable market and per‑patient revenue where pricing holds. This is a near‑term commercial positive if uptake follows. BizJournals: FDA clears higher dose of Wegovy
• Neutral Sentiment: Deutsche Bank and Citi gave broadly neutral takes: they find the pipeline encouraging but not yet transformative and flagged caution around oral GLP‑1 dynamics — meaning upside exists but may be incremental. Proactive: Novo Nordisk GLP-1 pipeline shows promise but oral drug trends give analysts pause
• Neutral Sentiment: Partnered programs are advancing (Novo initiated a Phase I study for a partnered oral obesity candidate), which diversifies development risk but is early stage for commercial impact. Yahoo Finance: LXRX Stock Up as NVO Initiates Phase I Study
• Negative Sentiment: Bernstein initiated coverage with an Underperform rating and a $175 price target, signaling expectations of further earnings downgrades and weighing on sentiment. Yahoo: Bernstein Initiates Coverage of Novo Nordisk With an Underperform Rating
• Negative Sentiment: Jefferies trimmed its target and reiterated concerns that GLP‑1 pricing erosion and uncertainty around the oral Wegovy launch could cannibalize or reduce franchise profitability. Proactive: Jefferies trims Novo Nordisk target
• Negative Sentiment: Novo cut Wegovy pricing in South Africa for a second time as competition (notably from Eli Lilly) intensifies—an example of real pricing pressure that could spread across markets. Reuters: Novo Nordisk cuts Wegovy price in South Africa for a second time
• Negative Sentiment: Market reaction: several market reports note the stock is trading lower amid the above mix of analyst downgrades and pricing/competitive concerns. Yahoo Finance: Novo Nordisk Stock Slides

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.